| Literature DB >> 30704410 |
Fabien Fily1,2, Jean-Baptiste Ronat3, Nada Malou3, Rupa Kanapathipillai4, Caroline Seguin3, Nagham Hussein5, Rasheed M Fakhri5, Céline Langendorf6.
Abstract
BACKGROUND: War-wounded civilians in Middle East countries are at risk of post-traumatic osteomyelitis (PTO). We aimed to describe and compare the bacterial etiology and proportion of first-line antibiotics resistant bacteria (FLAR) among PTO cases in civilians from Syria, Iraq and Yemen admitted to the reconstructive surgical program of Médecins Sans Frontières (MSF) in Amman, Jordan, and to identify risk factors for developing PTO with FLAR bacteria.Entities:
Keywords: Bone biopsy; First-line antibiotics resistance; Middle East; Osteomyelitis; War-wounded
Mesh:
Substances:
Year: 2019 PMID: 30704410 PMCID: PMC6357381 DOI: 10.1186/s12879-019-3741-9
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Demographic and clinical characteristics of patients with war-related post-traumatic osteomyelitis according to country, 2006–2016
| Iraq ( | Syria ( | Yemen ( |
| Total ( | ||
|---|---|---|---|---|---|---|
|
| ||||||
| Male | 276 (86.8) | 133 (95.0) | 91 (91.0) | .02 | 557 | 500 (89.6) |
| Age (years)a | 34 [27–43] | 26 [21.6–36] | 29 [21.5–32.5] | .001 | 557 | 31 [23–40] |
| Diabetes | 16 (5.1) | 4 (3.0) | 0 (0.0) | .057 | 527 | 20 (3.8) |
| Location of infection | .08 | 455 | ||||
| Upper extremity | 31 (14.3) | 32 (23.0) | 21 (21.0) | 84 (18.4) | ||
| Lower extremity | 185 (85.6) | 107 (76.9) | 79 (79.0) | 371 (81.5) | ||
| Previous surgeriesa | 4 [3–7] | 3 [1–5] | 3 [2–5] | .017 | 426 | 4 [2–6] |
| Delay since injuryb | 30 [12–64] | 8 [4–16] | 20 [11–36] | .001 | 466 | 19 [8–40] |
| Fixation | .89 | 423 | ||||
| Internal | 68 (32.9) | 49 (37.4) | 29 (34.1) | 146 (34.5) | ||
| External | 71 (34.2) | 42 (32.0) | 31 (36.4) | 144 (34.0) | ||
| No fixation | 68 (32.9) | 40 (30.5) | 25 (29.4) | 133 (31.4) | ||
| Polymicrobial infection | 69 (21.7) | 23 (16.4) | 16 (16.0) | .02 | 558 | 108 (19.3) |
aQuantitative variables are expressed with median [IQR]
btime between injury and bone tissue sample (months)
Fig. 1Percentage of micro-organism among total isolates from bone biopsies in war-wounded civilians according to country of origin, 2006–2016. *coagulase negative Staphylococcus
Proportion of first-line antibiotics resistant bacteria in war-related post-traumatic osteomyelitis according to country of origin, 2006–2016
| Organism | Iraq | Syria | Yemen |
| Total | ||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
| ||||||
| 3GC-REb | 129 | 111 (86.0) | 52 | 45 (86.5) | 44 | 38 (86.3) | .9 | 225 | 194 (86.2) |
| MRSAc | 102 | 68 (66.6) | 44 | 23 (52.2) | 44 | 24 (54.5) | .17 | 190 | 115 (60.5) |
| CRPAd | 48 | 27 (56.2) | 28 | 14 (50.0) | 10 | 5 (50.0) | .8 | 86 | 46 (53.4) |
| CRABe | 13 | 4 (30.7) | 6 | 4 (66.6) | 1 | 1 (100.0) | .2 | 20 | 9 (45.0) |
aNumber of isolates with susceptibility test result available for each type of bacteria
bEnterobacteriaceae resistant to third-generation cephalosporin
cS. aureus resistant to methicillin
dP. aeruginosa resistant to ceftazidime
eA. baumannii resistant to carbapenem
Fig. 2Trends of methicillin-resistant Staphylococcus aureus and third-generation cephalosporin resistant Enterobacteriaceae from war-related osteomyelitis in civilians from Iraq, Syria and Yemen. *methicillin-resistant Staphylococcus aureus, ** Enterobacteriaceae resistant to 3rd-generation cephalosporin
Drug resistance in isolates from bone biopsy cultures in war-wounded civilians from Iraq, Syria and Yemen
|
|
|
| ||||
|---|---|---|---|---|---|---|
|
|
|
| ||||
| Pip/tazob | 200 | 90 (45.0) | – | – | 84 | 21 (25.0) |
| Cefepime | 200 | 176 (88.0) | – | – | 77 | 67 (87.0) |
| Imipenem | 208 | 9 (4.3) | – | – | 95 | 6 (6.3) |
| Ertapenem | 85 | 8 (9.4) | – | – | – | – |
| Ciprofloxacin | 200 | 117 (58.5) | 177 | 74 (41.8) | 90 | 45 (50.0) |
| Cotrimoxazole | 179 | 150 (83.8) | 144 | 51 (35.4) | – | – |
| Erythromycin | – | – | 136 | 74 (54.4) | – | – |
| Clindamycin | – | – | 169 | 86 (50.8) | – | – |
| Rifampin | – | – | 149 | 66 (44.3) | – | – |
| Fusidic acid | – | – | 142 | 69 (48.6) | – | – |
aNumber of isolates with susceptibility test result available
bPiperacillin/tazobactam